Small Molecule to Target PSMA for Metastatic Hormone Refractory Prostate Cancer is under clinical development by Cellbion and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase II drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Small Molecule to Target PSMA for Metastatic Hormone Refractory Prostate Cancer’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Small Molecule to Target PSMA for Metastatic Hormone Refractory Prostate Cancer overview
Small molecule is under development for the treatment of metastatic castration resistant prostate cancer. It is administered by intravenous route. The drug candidate comprises of (GUL) Glu-Urea-Lys, a PSMA (prostate specific membrane antigen) chain, conjugated with the radioactive isotope Lu-177.
Cellbion overview
Cellbion is a company that specialises in the diagnosis of cardiovascular and cerebrovascular inflammations, as well as other disorders. The company is headquartered in Seoul, Republic of Korea (South Korea).
For a complete picture of Small Molecule to Target PSMA for Metastatic Hormone Refractory Prostate Cancer’s drug-specific PTSR and LoA scores, buy the report here.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.
